As the price of sequencing the human genome has fallen, parents of children with undiagnosed or rare diseases have become more willing to have their children's genomes sequenced, thus adding to the available data on genetic mutations. Expectations are high, but the technology leads to beneficial treatment in only about 1% of patients.

Related Summaries